Piper Sandler lowered shares of Accolade (NASDAQ:ACCD - Free Report) from a strong-buy rating to a hold rating in a report released on Wednesday, Marketbeat Ratings reports.
A number of other analysts have also weighed in on the stock. William Blair lowered shares of Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Leerink Partnrs downgraded Accolade from a "strong-buy" rating to a "hold" rating in a report on Wednesday, January 8th. Truist Financial cut Accolade from a "strong-buy" rating to a "hold" rating in a report on Friday, January 10th. Stifel Nicolaus reiterated a "hold" rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Finally, Stephens reaffirmed an "equal weight" rating and issued a $7.03 price target on shares of Accolade in a research note on Wednesday, February 12th. Thirteen research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $6.51.
Check Out Our Latest Research Report on ACCD
Accolade Price Performance
Shares of NASDAQ:ACCD remained flat at $6.96 during trading on Wednesday. The stock had a trading volume of 855,865 shares, compared to its average volume of 1,391,735. The company has a market cap of $570.67 million, a PE ratio of -3.09 and a beta of 2.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The stock has a 50 day moving average price of $6.49 and a two-hundred day moving average price of $4.69. Accolade has a 1-year low of $3.08 and a 1-year high of $10.68.
Accolade (NASDAQ:ACCD - Get Free Report) last posted its quarterly earnings data on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities research analysts anticipate that Accolade will post -1.2 earnings per share for the current year.
Hedge Funds Weigh In On Accolade
Several institutional investors have recently bought and sold shares of ACCD. Invesco Ltd. boosted its position in Accolade by 2.3% during the 4th quarter. Invesco Ltd. now owns 78,724 shares of the company's stock valued at $269,000 after acquiring an additional 1,804 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Accolade by 1.7% during the 4th quarter. Rhumbline Advisers now owns 115,136 shares of the company's stock worth $394,000 after purchasing an additional 1,967 shares during the last quarter. Centiva Capital LP boosted its position in Accolade by 5.8% during the third quarter. Centiva Capital LP now owns 59,660 shares of the company's stock valued at $230,000 after purchasing an additional 3,264 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Accolade by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,513,275 shares of the company's stock valued at $5,175,000 after purchasing an additional 3,885 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Accolade by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,673 shares of the company's stock valued at $95,000 after purchasing an additional 3,982 shares during the last quarter. 84.99% of the stock is owned by hedge funds and other institutional investors.
Accolade Company Profile
(
Get Free Report)
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Read More
Before you consider Accolade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.
While Accolade currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
